Monitoring statin safety in primary care

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 6, 2007, Pages 652-657

  Tragni, Elena ^a   Filippi, Alessandro ^b   Mazzaglia, Giampiero ^c   Sessa, Emiliano ^c   Cricelli, Claudio ^b   Catapano, Alberico L ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Italian College of General Practitioners   (Italy)

^c Health Search Database   (Italy)

Author keywords

Laboratory monitoring; Primary care; Safety; Statins

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CERIVASTATIN; CREATINE KINASE; CREATININE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HIGH RISK PATIENT; HUMAN; INFORMATION PROCESSING; ITALY; MAJOR CLINICAL STUDY; MALE; PHARMACEUTICAL CARE; PRESCRIPTION; PREVALENCE; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; CREATINE KINASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; PRIMARY HEALTH CARE;

EID: 34447282047     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1361     Document Type: Article

References (10)

1. Pasternak RC, Smith SC Jr, Bairey-Merz CN. et al. American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 2002; 106: 1024-1028.
2. Cricelli C, Mazzaglia G, Samani F, et al. Prevalence estimates for chronic diseases in Italy: exploring the differences between self-report and primary care databases. J Public Health Med 2003; 25: 254-257.
3. Sessa E, Samani F, Niccolai C, et al. La creazione di un campione validato di medici di medicina generale nel database di Health Search. SIMG 2004; 3: 10-14.
4. Lawrenson R, Williams T, Farmer R. Clinical information for research; the use of general practice databases. J Public Health Med 1999; 21: 299-304.
5. Filippi A. Sabatini A, Badioli L, et al. Effects of an automated electronic reminder in changing the antiplatelet drug-prescribing behaviour among Italian general practitioners in diabetic patients: an intervention trial. Diabetes Care 2003; 26: 1497-1500.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
7. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-1610.
8. Andrade SE, Donahue JG, Chan KA, et al. Liver function testing in patients on HMG-CoA reductase inhibitors. Pharmacoepidemiology and Drug Safety 2003; 12: 307-313.
9. Silva MA, Swanson AC, Gandhi PJ, et al. Statin-related adverse events: a meta-analysis. Clin Ther 2006; 23: 26-35.
10. Note AIFA 2004. Bollettino d'informazione sui farmaci 2004; 3-4: 99-161.